Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis[1][2].

Product Specifications

CAS Number

[1609391-90-3]

UNSPSC

12352005

Target

IFNAR; Interleukin Related; JAK

Type

Isotope-Labeled Compounds

Related Pathways

Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Purity

99.62

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC([2H])([2H])[2H])C1=NN=C(NC2=CC=CC=N2)C=C1NC3=CC=CC=C3S(=O)(C)=O

Molecular Formula

C18H15D3N6O3S

Molecular Weight

401.46

References & Citations

[1]Moslin R, et al. Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2) . J Med Chem. 2019 Oct 24;62 (20) :8953-8972.|[2]Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Oct 24;62 (20) :8973-8995.